Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer;: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization

被引:24
作者
Ruiz, M. I. Gallegos
Floor, K.
Vos, W.
Grunberg, K.
Meijer, G. A.
Rodriguez, J. A.
Giaccone, G.
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands
关键词
CISH; EGFR; FISH;
D O I
10.1111/j.1365-2559.2007.02854.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: The epidermal growth factor receptor (EGFR) is an important target for anticancer therapy. In non-small-cell lung cancer (NSCLC), mutations in the tyrosine kinase domain of EGFR and EGFR gene copy number have been demonstrated to identify patients most likely to benefit from EGFR tyrosine kinase inhibitors. EGFR gene copy number has been assessed mainly by fluorescence in situ hybridization (FISH), a method requiring the use of a fluorescence microscope and often hampered by the rapid fading of the fluorescent signal. These limitations of FISH can be overcome by using chromogenic in situ hybridization (CISH). To test the applicability of CISH for EGFR gene copy number testing in NSCLC, a comparison of CISH and FISH was performed. Methods: A total of 58 formalin-fixed, frozen NSCLC tissue samples were collected on which both CISH and FISH were performed. High concordance was found in the assessment of EGFR copy number between observers and between techniques (kappa coefficient = 0.64-0.76). CISH seemed the ideal technique for paraffin sections, whereas FISH was favourable for frozen material. Conclusions: CISH is a suitable alternative strategy to FISH in determining EGFR gene copy number in NSCLC patients.
引用
收藏
页码:631 / 637
页数:7
相关论文
共 18 条
[1]   Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials [J].
Bell, DW ;
Lynch, TJ ;
Haserlat, SM ;
Harris, PL ;
Okimoto, RA ;
Brannigan, BW ;
Sgroi, DC ;
Muir, B ;
Riemenschneider, MJ ;
Iacona, RB ;
Krebs, AD ;
Johnson, DH ;
Giaccone, G ;
Herbst, RS ;
Manegold, C ;
Fukuoka, M ;
Kris, MG ;
Baselga, J ;
Ochs, JS ;
Haber, DA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8081-8092
[2]   Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].
Cappuzzo, F ;
Hirsch, FR ;
Rossi, E ;
Bartolini, S ;
Ceresoli, GL ;
Bemis, L ;
Haney, J ;
Witta, S ;
Danenberg, K ;
Domenichini, I ;
Ludovini, V ;
Magrini, E ;
Gregorc, V ;
Doglioni, C ;
Sidoni, A ;
Tonato, M ;
Franklin, WA ;
Crino, L ;
Bunn, PA ;
Varella-Garcia, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655
[3]   Significance of EGFR protein expression and gene amplification in non-small cell luna carcinoma [J].
Dacic, Sanja ;
Flanagan, Melina ;
Cieply, Kathleen ;
Ramalingam, Suresh ;
Luketich, James ;
Belani, Chandra ;
Yousem, Samuel A. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 125 (06) :860-865
[4]  
Dziadziuszko R, 2005, CLIN CANCER RES, V11, p9028S
[5]   Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib [J].
Han, SW ;
Kim, TY ;
Hwang, PG ;
Jeong, S ;
Kim, J ;
Choi, IS ;
Oh, DY ;
Kim, LH ;
Kim, DW ;
Chung, DH ;
Im, SA ;
Kim, YT ;
Lee, JS ;
Heo, DS ;
Bang, YJ ;
Kim, NK .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2493-2501
[6]   Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study [J].
Hirsch, FR ;
Varella-Garcia, M ;
McCoy, J ;
West, H ;
Xavier, AC ;
Gumerlock, P ;
Bunn, PA ;
Franklin, WA ;
Crowley, J ;
Gandara, DR .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :6838-6845
[7]   Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis [J].
Hirsch, FR ;
Varella-Garcia, M ;
Bunn, PA ;
Di Maria, MV ;
Veve, R ;
Bremnes, RM ;
Barón, AE ;
Zeng, C ;
Franklin, WA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) :3798-3807
[8]   Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization [J].
Isola, J ;
Tanner, M ;
Forsyth, A ;
Cooke, TG ;
Watters, AD ;
Bartlett, JMS .
CLINICAL CANCER RESEARCH, 2004, 10 (14) :4793-4798
[9]   Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours [J].
Laakso, M. ;
Tanner, M. ;
Isola, J. .
JOURNAL OF PATHOLOGY, 2006, 210 (01) :3-9
[10]   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].
Lynch, TJ ;
Bell, DW ;
Sordella, R ;
Gurubhagavatula, S ;
Okimoto, RA ;
Brannigan, BW ;
Harris, PL ;
Haserlat, SM ;
Supko, JG ;
Haluska, FG ;
Louis, DN ;
Christiani, DC ;
Settleman, J ;
Haber, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139